bioAffinity Technologies, Inc. (BIAF)
Key Statistics
| Latest Price | $2.27 |
|---|---|
| Market Cap | $26.46M |
| Price Change ($) | $0.08 |
| Price Change (%) | 3.65% |
| Volume | 39.49K |
| Shares Outstanding | 11.66M |
| P/E Ratio | -2.44 |
| EPS | $-0.93 |
BIAF Chart
Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
About
CEO: Ms. Maria Zannes J.D.
Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Address: 22211 West Interstate 10, San Antonio, TX, US
Website: bioAffinity Technologies, Inc.
BIAF News
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).
accesswire.com
Read More
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients.
businesswire.com
Read More
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
businesswire.com
Read More
bioAffinity Technologies News Update
SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.
businesswire.com
Read More
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.
businesswire.com
Read More
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening.
businesswire.com
Read More
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share.
prnewswire.com
Read More
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.
businesswire.com
Read More
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NASDAQ: BIAF; BIAFW) has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.5625 per common share.
prnewswire.com
Read More
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.
businesswire.com
Read More
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.
businesswire.com
Read More
bioAffinity Technologies In The News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.
businesswire.com
Read More
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.
businesswire.com
Read More
bioAffinity Technologies In the News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.
businesswire.com
Read More
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET).
accesswire.com
Read More
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
businesswire.com
Read More
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024
SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
businesswire.com
Read More
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.
businesswire.com
Read More
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.
businesswire.com
Read More
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.
businesswire.com
Read More
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.
businesswire.com
Read More
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.
businesswire.com
Read More
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.
businesswire.com
Read More
AMA Issues CPT Code for bioAffinity Technologies' CyPath® Lung Test for Early-Stage Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AMA--The AMA has issued a CPT code specifically for bioAffinity Technologies' CyPath® Lung noninvasive test for early-stage lung cancer.
businesswire.com
Read More
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its financial results for the third quarter of 2022 and provided a business update. “Since our founding, bioAffinity Technologies has been dedicated to addressing the urgent need for noninvasive, early-stage cancer diagnosis and cancer treatment,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “Now that we have successfully raised the needed funds, we are confident that the outstanding scientific and commercialization team we have assembled will demonstrate the clinical value of CyPath® Lung in the marketplace. We will continue the development of additional non-invasive diagnostics for early-stage disease. With funds raised from our recent IPO and the exercise of warrants, bioAffinity Technologies also will pursue its promising research and development of broad-spectrum cancer therapeutics. “We have begun a limited test-market launch in the San Antonio area and recently have started to recognize revenue from sales of CyPath® Lung by our licensee, Precision Pathology Services, a CAP-accredited, CLIA-certified clinical pathology laboratory,” Zannes said. “The limited launch allows us to evaluate our marketing program and help ensure each step in the care pathway – from the initial order by physicians, to sputum collection and processing, to generating and delivering the patient report – is efficient and effective. This limited test-market approach allows us to refine future positioning and develop strategic insight for our CyPath® Lung test before expanding to a larger national market. We believe our current efforts will be essential to developing a strategic and cost-effective plan for a robust national rollout.” Corporate Highlights Award of Therapeutic Patents in China, Mexico and Australia: In October, the Company was pleased to announce that its wholly owned subsidiary, OncoSelect®, has been awarded patents to protect novel porphyrin-conjugated compounds for selective delivery of cancer treatments by the People’s Republic of China. Additionally, bioAffinity Technologies announced that Mexico and Australia recently awarded the Company therapeutic patents with claims directed to novel compounds of porphyrin-conjugates for selective delivery of cancer treatment. The patents grant protection to 2037. Presentation at CHEST Conference: Also in October, bioAffinity Technologies announced that results of its research into the use of flow cytometry for analyzing the lung environment to detect diseases of the lung were accepted for presentation at the American College of Chest Physicians (CHEST) 2022 conference. The data showed how flow cytometry can be used in development of diagnostics for COPD and asthma – similar to how the Company successfully uses flow cytometry in the CyPath® Lung test to detect early-stage lung cancer. Publication of Peer-Reviewed Results in PLOS ONE: In September, the Company announced publication of its research in high-throughput flow cytometry analysis of sputum in the journal, PLOS ONE. The article, titled Sputum analysis by flow cytometry; an effective platform to analyze the lung environment, reports on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung. Successful Closing of IPO: On September 6, bioAffinity Technologies announced the successful closing of its Initial Public Offering (IPO) of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Subsequent to the close of the IPO, the Company announced receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradeable warrants. Specifically, investors exercised a total of 725,576 tradeable warrants at a price of $7.35 per share and 310,910 non-tradeable warrants at a price of $7.656 per share. Combined with the Company’s underwritten public offering, the Company received an aggregate of approximately $15.6 million as of September 28, 2022. In addition, the Company converted almost $11 million in debt and related accrued interest as a result of the IPO. Financial Highlights bioAffinity Technologies reported revenue of about $1,150 for the three months ended September 30, 2022. There was no revenue to report the prior year. bioAffinity Technologies reported a net loss of $4.6 million or $1.10 per share, for the three months ended September 30, 2022, compared to a net loss of $1.5 million or $0.57 per share for the same period in 2021. Research and development expenses for the three months ended September 30, 2022, were $319,744 compared to $330,772 for the third quarter of 2021. The decrease is primarily due to a decrease in legal costs related to patents and annuities compared to the prior year. General and administrative expenses were $596,476 for the third quarter of 2022, compared to $161,549 for the same period in 2021. The increase was primarily attributable to an increase in consulting, legal and professional fees incurred in 2022 compared to 2021 and costs due to the activities associated with being a public company. Cash and cash equivalents totaled $13.5 million at September 30, 2022, compared to $1.4 million at December 31, 2021. In September 2022, the Company completed an Initial Public Offering resulting in net proceeds to the Company of approximately $15.6 million. Conference Call and Webcast Details bioAffinity Technologies will host a conference call and webcast today at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The webcast and subsequent replay may be accessed by visiting the Company’s website at https://ir.bioaffinitytech.com/. Please connect to the Company’s website at least 5 minutes prior to the webcast to ensure adequate time for any necessary software download. Alternately, please call 1-800-579-2543 (U.S.) or 1-203-518-9856 (international) to listen to the conference call. The conference ID for the call is BIAFQ322. Please dial in approximately 10 minutes prior to the call. The webcast will be available on the Company’s website for approximately 45 days. About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Precision Pathology Services licensed and developed CyPath® Lung as a Laboratory Developed Test (LDT) and has begun test marketing in Southeast Texas. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. bioAffinity Technologies, Inc. Unaudited Condensed Consolidated Balance sheets September 30, December 31, 2022 2020 (Unaudited) Current assets: Cash and cash equivalents $ 13,497,938 $ 1,360,638 Accounts and other receivables, net 9,930 1,530 Inventory 5,715 — Prepaid and other current assets 541,323 76,065 Total current assets 14,054,906 1,438,233 Deferred offering costs — 7,942 Property and equipment, net 1,781 4,633 Other assets 6,000 2,500 Total assets $ 14,062,687 $ 1,453,308 LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $ 149,867 $ 230,407 Accrued expenses 474,035 483,501 Accrued interest 25,168 1,121,392 Current portion of Paycheck Protection Program loan — 52,074 Loan payable 490,117 — Convertible notes payable 325,000 11,152,151 Total current liabilities 1,464,187 13,039,525 Paycheck Protection Program loan, less current portion — 160,184 Total liabilities 1,464,187 13,199,709 Commitments and contingencies Convertible preferred stock, par value $0.001 per share; 20,000,000 shares authorized; 0 and 5,296,044 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $0 and $5,825,648, at September 30, 2022 and December 31, 2021, respectively — 4,044,318 Stockholders’ equity (deficit): Preferred stock, no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively — — Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,369,750 issued and outstanding at September 30, 2022; and 2,677,140 shares issued and outstanding at December 31, 2021, respectively 58,588 18,740 Additional paid-in capital 47,232,797 12,703,896 Accumulated deficit (34,692,885 ) (28,513,355 ) Total stockholders’ equity (deficit) 12,598,500 (15,790,719 ) Total liabilities, convertible preferred stock, and stockholders’ equity $ 14,062,687 $ 1,453,308 bioAffinity Technologies, Inc. Unaudited Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ 1,150 $ — $ 2,457 $ — Cost of sales 146 — 292 — Gross profit 1,005 — 2,165 — Operating expenses: Research and development 319,744 330,772 949,388 877,674 Clinical development 60,941 33,972 141,684 78,241 General and administrative 596,476 161,549 1,298,409 591,155 Total operating expenses 977,161 526,293 2,389,481 1,547,070 Loss from operations (976,156 ) (526,293 ) (2,387,316 ) (1,547,070 ) Other income (expense): Interest income 3 19 850 24 Interest expense (589,091 ) (135,359 ) (2,135,941 ) (363,828 ) Gain on extinguishment of debt — — 212,258 239,200 Fair value adjustments on convertible notes payable (3,053,914 ) (852,161 ) (1,866,922 ) 924,099 Net loss before provision for income taxes (4,619,158 ) (1,513,794 ) (6,177,071 ) (747,575 ) Income tax expense (300 ) — (2,459 ) (1,950 ) Net income (loss) $ (4,619,458 ) $ (1,513,794 ) $ (6,179,530 ) $ (749,525 ) Net loss per common share, basic and diluted $ (1.10 ) $ (0.57 ) $ (1.93 ) $ (0.28 ) Weighted average common shares outstanding 4,203,781 2,675,054 3,194,765 2,674,924
businesswire.com
Read MoreAnnual Income Statement
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Revenue | $2.53M | $4.80K | $- | $- | $- |
| Cost of Revenue | $1.99M | $-0.00B | $4.82K | $22.24K | $40.28K |
| Gross Profit | $542.02K | $4.34K | $-4.82K | $-22.24K | $-40.28K |
| Gross Profit Ratio | 21.40% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.72M | $1.29M | $1.33M | $1.61M | $1.85M |
| General and Administrative Expenses | $6.79M | $2.73M | $880.77K | $994.34K | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.79M | $2.73M | $880.77K | $994.34K | $1.20M |
| Other Expenses | $-27.80K | $-1.87M | $724.93K | $-4.28M | $- |
| Operating Expenses | $8.52M | $4.02M | $2.21M | $2.60M | $3.05M |
| Cost and Expenses | $10.51M | $4.02M | $2.21M | $2.60M | $3.09M |
| Interest Income | $122.13K | $46.71K | $-0.00B | $1.07K | $2.78K |
| Interest Expense | $37.12K | $2.53M | $1.00M | $382.17K | $214.83K |
| Depreciation and Amortization | $249.59K | $-1.81M | $730.17K | $-4.26M | $40.28K |
| EBITDA | $-7.72M | $-5.82M | $-1.48M | $-6.86M | $-3.05M |
| EBITDA Ratio | -304.98% | -121196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-7.97M | $-4.01M | $-2.21M | $-2.60M | $-3.09M |
| Operating Income Ratio | -314.84% | -83511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $57.21K | $-4.14M | $-4.12M | $-4.66M | $-212.06K |
| Income Before Tax | $-7.92M | $-8.15M | $-6.32M | $-7.27M | $-3.30M |
| Income Before Tax Ratio | -312.58% | -169720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $20.99K | $2.46K | $1.95K | $2.75K | $3.20K |
| Net Income | $-7.94M | $-8.15M | $-6.33M | $-7.27M | $-3.31M |
| Net Income Ratio | -313.41% | -169771.25% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.91 | $-1.81 | $-0.86 | $-0.99 | $-0.45 |
| EPS Diluted | $-0.91 | $-1.81 | $-0.86 | $-0.99 | $-0.45 |
| Weighted Average Shares Outstanding | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Average Shares Outstanding Diluted | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.41M | $2.21M | $298.48K | $19.74K | $-0.00B | $2.35K | $1.15K | $1.31K | $- | $- | $- | $- | $- |
| Cost of Revenue | $1.72M | $1.81M | $74.70K | $1.23K | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $- | $- | $- | $- | $- |
| Gross Profit | $683.31K | $399.71K | $223.78K | $18.50K | $-0.00B | $2.17K | $1.00K | $1.16K | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 28.40% | 18.06% | 74.97% | 93.75% | 90.55% | 92.54% | 87.30% | 88.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $442.60K | $528.17K | $330.38K | $370.38K | $389.25K | $197.25K | $380.69K | $335.87K | $374.52K | $370.13K | $364.74K | $286.95K | $304.22K |
| General and Administrative Expenses | $- | $2.21M | $2.02M | $1.43M | $- | $1.30M | $596.48K | $349.41K | $352.52K | $289.62K | $161.55K | $242.62K | $186.99K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $130.25K | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.19M | $2.21M | $2.02M | $1.43M | $1.17M | $1.43M | $596.48K | $349.41K | $352.52K | $289.62K | $161.55K | $242.62K | $186.99K |
| Other Expenses | $4.51K | $-15.30K | $89.29K | $34.03M | $19.54M | $85.06K | $-3.05M | $782.80K | $404.19K | $-199.17K | $-852.16K | $1.89M | $-111.48K |
| Operating Expenses | $2.63M | $2.74M | $2.44M | $1.80M | $1.56M | $1.63M | $977.16K | $685.28K | $727.04K | $659.75K | $526.29K | $529.57K | $491.21K |
| Cost and Expenses | $4.35M | $4.56M | $2.52M | $1.80M | $1.56M | $1.63M | $977.31K | $685.43K | $727.04K | $659.75K | $526.29K | $529.57K | $491.21K |
| Interest Income | $6.13K | $12.16K | $27.19K | $44.12K | $37.00K | $45.86K | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $- | $-0.00B |
| Interest Expense | $23.55K | $25.32K | $-8.79K | $1.36K | $37.00M | $96.70K | $889.09K | $399.26K | $1.15M | $638.03K | $135.36K | $116.92K | $111.55K |
| Depreciation and Amortization | $149.64K | $148.79K | $57.57K | $21.55K | $21.68K | $53.19K | $-3.05M | $1.04K | $405.80K | $-0.00B | $1.19K | $1.19K | $1.64K |
| EBITDA | $-1.80M | $-2.19M | $-2.24M | $-1.71M | $-1.54M | $-1.57M | $-4.03M | $312.25K | $-321.24K | $-857.73K | $-1.38M | $1.60M | $-601.04K |
| EBITDA Ratio | -74.62% | -99.11% | -751.93% | -8677.04% | -166806.19% | -66946.04% | -350373.39% | 23909.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-1.95M | $-2.34M | $-2.29M | $-1.78M | $-1.56M | $-1.62M | $-976.16K | $311.21K | $-727.04K | $-659.75K | $-526.29K | $-529.57K | $-491.21K |
| Operating Income Ratio | -80.84% | -105.83% | -768.72% | -9009.78% | -169160.69% | -69213.21% | -84883.13% | 23829.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-12.91K | $-28.46K | $5.91K | $42.76M | $37.00K | $-50.84K | $-3.94M | $-399.26K | $-742.82K | $-4.28M | $-852.16K | $2.13M | $-111.48K |
| Income Before Tax | $-1.96M | $-2.37M | $-2.29M | $-1.74M | $-1.52M | $-1.67M | $-4.92M | $-88.05K | $-1.47M | $-5.58M | $-1.51M | $1.48M | $-714.23K |
| Income Before Tax Ratio | -81.37% | -107.12% | -766.74% | -8793.12% | -165143.43% | -71380.35% | -427752.87% | -6742.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $3.67K | $2.29K | $-2.29K | $4.59K | $11.82K | $2.16K | $-0.00B | $399.26K | $2.16K | $438.86K | $-716.80K | $2.24M | $1.95K |
| Net Income | $-1.96M | $-2.37M | $-2.29M | $-1.74M | $-1.53M | $-1.68M | $-4.92M | $-487.32K | $-1.47M | $-5.58M | $-1.51M | $1.48M | $-716.18K |
| Net Income Ratio | -81.53% | -107.22% | -767.51% | -8816.36% | -166426.71% | -71472.38% | -427778.96% | -37313.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.20 | $-0.26 | $-0.26 | $-0.20 | $-0.18 | $-0.20 | $-1.17 | $-0.18 | $-0.55 | $0.00 | $-0.55 | $0.54 | $-0.26 |
| EPS Diluted | $-0.20 | $-0.26 | $-0.26 | $-0.20 | $-0.18 | $-0.20 | $-1.17 | $-0.18 | $-0.54 | $0.00 | $-0.55 | $0.54 | $-0.26 |
| Weighted Average Shares Outstanding | 9.92M | 9.25M | 8.70M | 8.52M | 8.43M | 8.38M | 4.20M | 2.69M | 2.68M | 2.68M | 2.68M | 2.73M | 2.67M |
| Weighted Average Shares Outstanding Diluted | 9.92M | 9.25M | 8.70M | 8.52M | 8.43M | 8.38M | 4.20M | 2.73M | 2.73M | 2.73M | 2.73M | 2.73M | 2.73M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.82M | $11.41M | $1.36M | $83.11K | $578.48K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $2.82M | $11.41M | $1.36M | $83.11K | $578.48K |
| Net Receivables | $811.67K | $10.49K | $1.53K | $1.53K | $1.53K |
| Inventory | $18.48K | $5.54K | $71.85K | $28.35K | $- |
| Other Current Assets | $321.02K | $119.77K | $4.22K | $5.67K | $37.49K |
| Total Current Assets | $3.97M | $11.96M | $1.44M | $118.66K | $617.51K |
| Property Plant Equipment Net | $1.99M | $214.44K | $4.63K | $9.45K | $28.80K |
| Goodwill | $1.40M | $- | $- | $- | $- |
| Intangible Assets | $833.47K | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $2.24M | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $16.06K | $6.00K | $10.44K | $17.50K | $12.50K |
| Total Non-Current Assets | $4.25M | $220.44K | $15.07K | $26.95K | $41.30K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $8.22M | $12.18M | $1.45M | $145.60K | $658.81K |
| Account Payables | $604.79K | $345.04K | $230.41K | $191.39K | $103.42K |
| Short Term Debt | $460.17K | $251.75K | $11.20M | $9.95M | $4.01M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $33.06K | $- | $- | $- | $- |
| Other Current Liabilities | $1.15M | $541.89K | $1.60M | $976.10K | $579.93K |
| Total Current Liabilities | $2.25M | $1.14M | $13.04M | $11.12M | $4.69M |
| Long Term Debt | $1.12M | $- | $160.18K | $53.47K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $596.79K | $4.04M | $4.04M | $- |
| Total Non-Current Liabilities | $1.12M | $596.79K | $4.20M | $4.10M | $- |
| Other Liabilities | $- | $-596.79K | $--0.00B | $- | $- |
| Total Liabilities | $3.37M | $1.14M | $17.24M | $15.22M | $4.69M |
| Preferred Stock | $- | $12.18B | $4.04M | $4.04M | $4.04M |
| Common Stock | $65.76K | $58.67K | $18.74K | $18.72K | $18.72K |
| Retained Earnings | $-44.60M | $-36.67M | $-28.51M | $-22.19M | $-14.92M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-4.04M | $-4.04M | $-18.72K |
| Other Total Stockholders Equity | $49.39M | $-12.13B | $12.70M | $7.10M | $6.84M |
| Total Stockholders Equity | $4.86M | $11.04M | $-15.79M | $-15.07M | $-4.04M |
| Total Equity | $4.86M | $11.04M | $-15.79M | $-15.07M | $-4.04M |
| Total Liabilities and Stockholders Equity | $8.22M | $12.18M | $1.45M | $145.60K | $658.81K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $8.22M | $12.18M | $1.45M | $145.60K | $658.81K |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $1.58M | $251.75K | $11.36M | $10.01M | $4.01M |
| Net Debt | $-1.24M | $-11.16M | $10.00M | $9.92M | $3.43M |
Quarterly Balance Sheet
| Breakdown | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.45M | $2.82M | $4.51M | $8.28M | $9.77M | $11.41M | $13.50M | $214.40K | $1.03M | $1.36M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $2.45M | $2.82M | $4.51M | $8.28M | $9.77M | $11.41M | $13.50M | $214.40K | $1.03M | $1.36M |
| Net Receivables | $1.12M | $811.67K | $1.11M | $90.23K | $11.03K | $10.49K | $9.93K | $7.82K | $6.86K | $1.53K |
| Inventory | $9.49K | $18.48K | $9.91K | $10.10K | $11.34K | $5.54K | $5.71K | $5.66K | $5.80K | $71.85K |
| Other Current Assets | $344.90K | $321.02K | $142.11K | $128.19K | $134.31K | $119.77K | $8.83K | $15.53K | $17.42K | $4.22K |
| Total Current Assets | $3.93M | $3.97M | $6.01M | $8.66M | $10.23M | $11.96M | $14.05M | $327.25K | $1.11M | $1.44M |
| Property Plant Equipment Net | $1.88M | $1.99M | $2.17M | $207.38K | $225.07K | $214.44K | $1.78K | $2.55K | $3.59K | $4.63K |
| Goodwill | $1.40M | $1.40M | $1.15M | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $818.89K | $833.47K | $848.06K | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $2.22M | $2.24M | $2.00M | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $16.06K | $16.06K | $16.06K | $6.92K | $6.92K | $6.00K | $6.00K | $610.95K | $243.80K | $10.44K |
| Total Non-Current Assets | $4.12M | $4.25M | $4.18M | $214.30K | $231.99K | $220.44K | $7.78K | $613.50K | $247.40K | $15.07K |
| Other Assets | $--0.00B | $- | $--0.00B | $--0.00B | $- | $- | $- | $- | $- | $- |
| Total Assets | $8.05M | $8.22M | $10.19M | $8.87M | $10.46M | $12.18M | $14.06M | $940.75K | $1.35M | $1.45M |
| Account Payables | $383.99K | $604.79K | $827.41K | $174.40K | $146.54K | $345.04K | $149.87K | $585.15K | $247.69K | $230.41K |
| Short Term Debt | $474.10K | $460.17K | $449.14K | $42.33K | $168.43K | $251.75K | $815.12K | $11.12M | $11.78M | $11.20M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $30.17K | $33.06K | $38.25K | $42.75K | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $883.32K | $1.15M | $643.79K | $515.66K | $481.34K | $541.89K | $499.20K | $1.97M | $1.86M | $1.60M |
| Total Current Liabilities | $1.77M | $2.25M | $1.96M | $775.15K | $796.30K | $1.14M | $1.46M | $13.68M | $13.88M | $13.04M |
| Long Term Debt | $23.04K | $1.12M | $1.24M | $- | $- | $- | $- | $- | $149.69K | $160.18K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $997.59K | $- | $- | $- | $146.54M | $596.79K | $474.87K | $4.04M | $4.04M | $4.04M |
| Total Non-Current Liabilities | $1.02M | $1.12M | $1.24M | $- | $146.54M | $596.79K | $474.87K | $4.04M | $4.19M | $4.20M |
| Other Liabilities | $- | $- | $- | $- | $-146.54M | $-596.79K | $-474.87K | $- | $- | $- |
| Total Liabilities | $2.79M | $3.37M | $3.20M | $775.15K | $796.30K | $1.14M | $1.46M | $17.73M | $18.08M | $17.24M |
| Preferred Stock | $- | $- | $-0.00B | $-0.00B | $-0.00B | $- | $14.06B | $4.04M | $- | $- |
| Common Stock | $78.52K | $65.76K | $64.53K | $59.89K | $59.24K | $58.67K | $58.59K | $18.86K | $18.85K | $18.74K |
| Retained Earnings | $-46.57M | $-44.60M | $-42.23M | $-39.94M | $-38.20M | $-36.67M | $-34.99M | $-30.07M | $-29.99M | $-28.51M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-0.00B | $--0.00B | $--0.00B | $- | $- | $-4.04M | $- | $- |
| Other Total Stockholders Equity | $51.74M | $49.39M | $49.16M | $47.98M | $47.81M | $47.65M | $-14.02B | $13.27M | $13.24M | $12.70M |
| Total Stockholders Equity | $5.26M | $4.86M | $6.99M | $8.10M | $9.67M | $11.04M | $12.60M | $-16.79M | $-16.72M | $-15.79M |
| Total Equity | $5.26M | $4.86M | $6.99M | $8.10M | $9.67M | $11.04M | $12.60M | $-16.79M | $-16.72M | $-15.79M |
| Total Liabilities and Stockholders Equity | $8.05M | $8.22M | $10.19M | $8.87M | $10.46M | $12.18M | $14.06M | $940.75K | $1.35M | $1.45M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $8.05M | $8.22M | $10.19M | $8.87M | $10.46M | $12.18M | $14.06M | $940.75K | $1.35M | $1.45M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $1.49M | $1.58M | $1.69M | $42.33K | $168.43K | $251.75K | $815.12K | $11.12M | $11.93M | $11.36M |
| Net Debt | $-958.44K | $-1.24M | $-2.82M | $-8.24M | $-9.60M | $-11.16M | $-12.68M | $10.91M | $10.90M | $10.00M |
Annual Cash Flow Statement
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Net Income | $-7.94M | $-8.15M | $-6.33M | $-7.27M | $-3.31M |
| Depreciation and Amortization | $249.59K | $10.18K | $4.82K | $22.24K | $40.28K |
| Deferred Income Tax | $-964.09K | $- | $3.84M | $- | $- |
| Stock Based Compensation | $748.82K | $248.59K | $43.01K | $275.73K | $- |
| Change in Working Capital | $900.79K | $114.20K | $632.82K | $482.62K | $322.01K |
| Accounts Receivables | $311.37K | $-8.96K | $- | $- | $-0.00B |
| Inventory | $-12.94K | $-5.54K | $- | $- | $- |
| Accounts Payables | $-14.50K | $114.64K | $39.02K | $87.97K | $-39.82K |
| Other Working Capital | $616.87K | $14.07K | $593.80K | $394.65K | $361.54K |
| Other Non Cash Items | $964.09K | $3.71M | $-244.35K | $4.28M | $575.11K |
| Net Cash Provided by Operating Activities | $-6.04M | $-4.07M | $-2.05M | $-2.21M | $-2.49M |
| Investments in Property Plant and Equipment | $-22.90K | $-219.99K | $- | $-2.89K | $-11.40K |
| Acquisitions Net | $-2.19M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-2.21M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-2.21M | $-219.99K | $- | $-2.89K | $-11.40K |
| Debt Repayment | $-344.98K | $-694.98K | $-3.51M | $-1.72M | $-2.33M |
| Common Stock Issued | $- | $6.03M | $- | $- | $- |
| Common Stock Repurchased | $- | $--0.00B | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-344.98K | $9.01M | $6.83M | $3.43M | $- |
| Net Cash Used Provided by Financing Activities | $-344.98K | $14.34M | $3.33M | $1.72M | $2.33M |
| Effect of Forex Changes on Cash | $-0.00B | $- | $- | $- | $- |
| Net Change in Cash | $-8.59M | $10.05M | $1.28M | $-495.38K | $-166.59K |
| Cash at End of Period | $2.82M | $11.41M | $1.36M | $83.11K | $578.48K |
| Cash at Beginning of Period | $11.41M | $1.36M | $83.11K | $578.48K | $745.08K |
| Operating Cash Flow | $-6.04M | $-4.07M | $-2.05M | $-2.21M | $-2.49M |
| Capital Expenditure | $-22.90K | $-219.99K | $- | $-2.89K | $-11.40K |
| Free Cash Flow | $-6.06M | $-4.29M | $-2.05M | $-2.21M | $-2.50M |
Quarterly Cash Flow Statement
| Breakdown | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.96M | $-2.37M | $-2.29M | $-1.74M | $-1.53M | $-1.67M | $-4.92M | $-88.05K | $-1.47M | $-5.58M | $-1.51M | $1.48M | $-716.18K |
| Depreciation and Amortization | $149.64K | $148.79K | $57.57K | $21.55K | $21.68K | $7.33K | $-0.00B | $1.04K | $1.04K | $-0.00B | $1.19K | $1.19K | $1.64K |
| Deferred Income Tax | $- | $-722.47K | $-4.84B | $170.25M | $-405.82K | $- | $- | $- | $- | $4.08M | $- | $-239.20K | $- |
| Stock Based Compensation | $283.71K | $234.51K | $186.44K | $170.25K | $157.61K | $36.85K | $79.01K | $26.68K | $106.05K | $-89.52K | $-20.31K | $94.58K | $58.25K |
| Change in Working Capital | $-817.51K | $373.56K | $514.36K | $188.42K | $-175.55K | $247.09K | $-742.04K | $452.20K | $156.94K | $253.09K | $39.42K | $188.06K | $152.26K |
| Accounts Receivables | $-311.94K | $239.53K | $-64.72K | $-79.20K | $-538.00K | $-8.96K | $-2.11K | $--0.00B | $- | $- | $- | $- | $- |
| Inventory | $9.00K | $-8.58K | $-0.00B | $1.23K | $-5.79K | $-0.00B | $--0.00B | $-0.00B | $-5.80K | $- | $- | $- | $- |
| Accounts Payables | $-220.80K | $-421.34K | $577.47K | $27.87K | $-198.50K | $195.36K | $-435.29K | $337.28K | $17.28K | $-29.08K | $-89.66K | $100.52K | $57.23K |
| Other Working Capital | $-293.77K | $563.95K | $1.41K | $238.52K | $566.75K | $60.52K | $-304.58K | $115.74K | $145.46K | $282.17K | $129.07K | $87.53K | $95.02K |
| Other Non Cash Items | $1.11M | $722.47K | $4.84B | $-170.25M | $405.82K | $82.68K | $3.82M | $-768.02K | $574.02K | $679.75K | $852.16K | $-1.89M | $111.48K |
| Net Cash Provided by Operating Activities | $-2.35M | $-1.62M | $-1.53M | $-1.36M | $-1.53M | $-1.30M | $-1.76M | $-376.14K | $-633.97K | $-652.44K | $-641.33K | $-362.66K | $-392.55K |
| Investments in Property Plant and Equipment | $-41.39K | $13.44K | $--0.00B | $-3.86K | $-32.31K | $-219.99K | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $2.19M | $-2.19M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-2.21M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-41.39K | $13.44K | $-2.19M | $-3.86K | $-32.31K | $-219.99K | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $-60.94K | $-84.81K | $-50.77K | $-126.10K | $-83.32K | $-563.37K | $-31.61K | $-34.97K | $- | $- | $- | $- | $- |
| Common Stock Issued | $2.08M | $-6.03B | $6.03B | $- | $- | $6.03M | $14.34M | $-402.52K | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $--0.00B | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $102.62M | $6.03B | $-50.77K | $-126.10K | $-83.32K | $-6.03M | $739.12K | $-437.49K | $301.36K | $- | $- | $650.00K | $537.26K |
| Net Cash Used Provided by Financing Activities | $2.02M | $-84.81K | $-50.77K | $-126.10K | $-83.32K | $-563.56K | $15.04M | $-437.49K | $301.36K | $1.77M | $370.00K | $650.00K | $537.26K |
| Effect of Forex Changes on Cash | $- | $-1.36B | $1.19B | $171.74M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-368.40K | $-1.69M | $-3.77M | $-1.49M | $-1.64M | $-2.08M | $13.28M | $-813.63K | $-332.60K | $1.12M | $-271.33K | $287.34K | $144.71K |
| Cash at End of Period | $2.45M | $2.82M | $4.51M | $8.28M | $9.77M | $11.41M | $13.50M | $214.40K | $1.03M | $1.36M | $243.83K | $515.16K | $227.82K |
| Cash at Beginning of Period | $2.82M | $4.51M | $8.28M | $9.77M | $11.41M | $13.50M | $214.40K | $1.03M | $1.36M | $243.83K | $515.16K | $227.82K | $83.11K |
| Operating Cash Flow | $-2.35M | $-1.62M | $-1.53M | $-1.36M | $-1.53M | $-1.30M | $-1.76M | $-376.14K | $-633.97K | $-652.44K | $-641.33K | $-362.66K | $-392.55K |
| Capital Expenditure | $-41.39K | $13.44K | $--0.00B | $-3.86K | $-32.31K | $-219.99K | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-2.39M | $-1.60M | $-1.53M | $-1.36M | $-1.56M | $-1.52M | $-1.76M | $-376.14K | $-633.97K | $-652.44K | $-641.33K | $-362.66K | $-392.55K |
Coming soon...
Dividend Yield
0.00%
Dividend Payout Ratio
0.00x
Dividend Paid & Capex Coverage Ratio
263.64x
Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|
Key Metrics
Financial Ratios
| Price to Earnings Ratio | -1.62x |
|---|---|
| Price to Book Ratio | 2.65x |
| Current Ratio | 1.77x |
| Quick Ratio | 1.62x |
| Cash Ratio | 1.26x |
| Debt to Equity | 0.33x |
| Return on Invested Capital | -1.24x |
| Return on Equity | -1.63x |
| Return on Assets | -0.97x |
Key Metrics
| Enterprise Value | $11.62M |
|---|---|
| Revenue Per Share | $0.29 |
| Net Income Per Share | $-0.91 |
| Operating Cash Flow Per Share | $-0.69 |
| Free Cash Flow Per Share | $-0.69 |
| Cash Per Share | $0.32 |
| Gross Profit Margin | 0.21% |
| Operating Profit Margin | -3.15% |
| Net Profit Margin | -1.63% |
Financial Growth
| Revenue Growth | 526.27% |
|---|---|
| Gross Profit Growth | 124.01% |
| EPS Growth | 0.50% |
| EBIT Growth | -0.99% |
| Operating Income Growth | -0.99% |
| Revenue Growth | 526.27% |
| Net Income Growth | 0.03% |
| Dividend Per Share Growth | 0.00% |
| Free Cash Flow Growth | -0.41% |
Coming soon...
Data provided by IEX Cloud & Financial Modeling Prep
Disclaimer: The content of this website is not to be intended as investment advice. The material is provided for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation or endorsement for any security or strategy, nor does it constitute an offer to provide investment advisory or other services by MLQ. MLQ makes no guarantees regarding the accuracy and completeness of the information expressed in this website. See our full Terms of Service for more information.